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phosphatase activity was observed and
shown to be reversible, the protein
tyrosine phosphatase activity measured
in MBCD-treated keratinocytes was not
significantly different at any time point
when compared with the activity mea-
sured in untreated cells, indicating that
disorganization of lipid rafts does not
cause inactivation of protein tyrosine
phosphatases. Similarly, detection of
protein oxidation showed that cultures
subjected to H2O2 treatment presented
important protein oxidation, which was
partially protected by preincubation with
NAC (Figure 2b), but in untreated and in
cholesterol-depleted cultures, protein
oxidation was never detected. Finally,
an ultimate experiment was performed
in which intracellular ROS synthesis was
directly measured by a fluorescent dye.
Hydrogen peroxide induced a strong
intracellular ROS production during the
first 20minutes, which was clearly de-
creased when preincubation with NAC
was performed. ROS measurements
showed that keratinocytes with a per-
turbed lipid raft organization presented
only very low ROS levels, which were
even below the baseline ROS levels
measured in untreated cells (Figure 2c).
In other words, all these results suggest
that disruption of lipid rafts is rather able
to inhibit the basal ROS production, an
observation that is in total accordance
with recent literature showing that
MBCD treatment protects yeast cells
from oxidative stress (Du and Ayscough,
2009). In conclusion, contrary to the
hypothesis suggested by our previous
study (Mathay et al., 2008), the data
presented hereby clearly point out that
lipid raft disruption by cholesterol deple-
tion does not modulate the cellular redox
balance toward oxidation in normal
keratinocytes. To pursue the identifica-
tion of mechanisms involved in kerati-
nocytes after cholesterol depletion, we
have now undertaken transcriptional
profiling. This unbiased approach should
help to elucidate major actors, mechan-
isms, and pathways involved during and
after lipid raft disruption in epidermal
keratinocytes.
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TO THE EDITOR
The number of atopic dermatitis (AD)
patients has been increasing steadily
worldwide. AD is a dangerous disorder
because it not only causes chronic
inflammation but also leads to bacterial
and viral skin infections. Although the
pathogenesis of AD is not completely
understood, inflammation-related an-
giogenesis (Groneberg et al., 2005)
and cytokine production associated
with T helper type 2 (Th2) polarization
Abbreviations: AD, atopic dermatitis; TA, tannic acid; TARC, thymus and activation-regulated
chemokine; TSLP, thymic stromal lymphopoietin
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have been reported to be key mediators
of AD development (Ong et al., 2002;
Howell, 2007). We therefore thought
that blocking these processes might be
an effective therapeutic approach for
the treatment of AD.
Recently, several effective therapies
and agents involving polyphenolic
compounds have been introduced for
AD treatment (Gottlieb, 2005). The
well-known polyphenolic compounds
tannic acid (TA) and quercetin have a
documented anti-inflammatory effect as
well as a role in balancing Th1 and Th2
responses in inflammatory human der-
mal fibroblasts (Park et al., 2006, 2009;
Rogerio et al., 2007). On the basis of
these reports, we hypothesized that TA
and quercetin are able to inhibit AD
development and investigated the ther-
apeutic effect of these compounds on
AD-like skin lesions.
In AD, production of vascular en-
dothelial growth factor (VEGF) is en-
hanced. VEGF acts as a proangiogenic
factor and induces hyperpermeability of
blood vessels, and several reports have
suggested that inhibition of its produc-
tion or blockade of its action may be
an effective new therapeutic strategy for
treating AD (Zhang et al., 2006; Ip
et al., 2007). However, VEGF suppres-
sion by polyphenolic compounds in AD
models is not yet clearly understood.
Although both TA (Bawadi et al., 2005;
Wen et al., 2008) and quercetin have
been shown to reduce VEGF levels in
various cancer cells (Zhong et al.,
2006; Luo et al., 2008). However, little
is known about their effect on AD-like
disease pathology.
To investigate the effect of TA
and quercetin on angiogenesis asso-
ciated with AD, we first measured
VEGF levels in the human keratinocyte
cell line, HaCaT, using PCR after treat-
ment with various doses of TA and
quercetin. Because tumor necrosis factor
(TNF)-a has a role in AD development
(Trompezinski et al., 2004) and induces
VEGF production in human keratino-
cytes, HaCaT cells were pretreated with
TNF-a for 1 hour, followed by treatment
with TA and quercetin. TA and querce-
tin decreased the expression level of the
TNF-a-induced proangiogenic factor,
VEGF, in a dose-dependent manner
(Figure 1a). To study the combined
effect of TA (25 mM) and quercetin
(5 mM), we administered the compounds
either individually or in combination
and determined VEGF expression level
using PCR and ELISA (RayBiotech,
Norcross, GA). Interestingly, treatment
with both TA and quercetin showed a
more powerful effect than treatment
with either agent alone (Figure 1b and c).
This suggests that the combination of
TA and quercetin acts as a powerful
VEGF suppressor in keratinocytes.
Because the expression level of
VEGF correlates with the level of
angiogenesis (Carmeliet and Jain,
2000), we were interested in investigat-
ing whether treatment with both TA and
quercetin had a therapeutic effect and
was associated with angiogenesis
in vivo. We divided Nc/Nga
mice (Biostar AD, Kobe-shi, Japan) into
three groups: a normal healthy group
(negative control), an AD control group
(after AD induction, only phosphate-
buffered saline was applied to AD skin
lesions), and a TA (25mM) and querce-
tin (2.5mM) cotreatment group (after
AD induction, TA and quercetin were
applied to AD lesions). Induction of AD
in Nc/Nga mice was accomplished by
applying house dust mite allergens
(Biostar AD, Japan) to the ears for 3
weeks. The effects of treatment were
then assessed for 3 weeks at the site of
AD induction. As shown in Figure 1d,
gross clinical assessment showed that
mice treated with TA and quercetin
showed significant improvement in
symptoms and appeared similar to the
normal healthy group.
At the end of treatment, skin lesions
were excised, sectioned, and stained
with hematoxylin and eosin for histo-
pathological analysis. Compared with
the AD control group, the group treated
with TA and quercetin showed a clear
reduction in ear and epidermal thick-
ness and decreased infiltration of leu-
kocytes. These data suggest that the
application of TA and quercetin has a
therapeutic effect on AD, resulting in
milder symptoms and a reduced AD
score (Figure 1e).
Angiogenesis level was measured
using immunohistochemical staining
for CD31, which is commonly used
for vessel detection (Saban et al., 2007).
As expected, the expression of CD31 in
the group treated with TA and quercetin
Figure 1. Therapeutic effect of tannic acid (TA) and quercetin on atopic dermatitis (AD) by suppressing angiogenesis. HaCaT cells were pretreated with or
without tumor necrosis factor (TNF)-a (50 ngml1) for 1 hour, followed by treatment with (a) 0, 10, 25, and 50 mM of TA and 0, 1, 5, and 10mM of quercetin for
6 hours. (b) HaCaT cells were pretreated with or without TNF-a (50 ngml1) for 1 hour, followed by treatment with 25 mM of TA and 5 mM of quercetin, separately
or in combination for 6 hours. Cells were then harvested, total RNA was isolated, and cDNA was synthesized. Real-time PCR analysis was performed to detect
vascular endothelial growth factor (VEGF) mRNA. Data are expressed as the ratio of VEGF to b-actin mRNA expression. (c) HaCaT cells and human primary
keratinocytes were pretreated with or without TNF-a (50 ngml1) for 1 hour, followed by treatment with 25 mM of TA and 5 mM of quercetin—separately or in
combination—for 24 hours. The supernatant levels of VEGF were determined using human VEGF-specific ELISA kits. Results are from one representative
experiment of three separate experiments. The data are reported as mean±SD. *Po0.05, () control group versus TNF-a-treated group. yPo0.05, TNF-a-treated
group versus group treated with TA and quercetin. (d) House dust mite allergens were applied to the ears of Nc/Nga mice three times a week for 3 weeks.
Treatment was administered with or without TA (25mM) and quercetin (2.5mM) three times a week on Nc/Nga mice with induced AD, and treatment effects
were assessed for 3 weeks. At the treatment end points, gross assessment (top) and histological analysis (bottom) were carried out on ear skin with induced AD.
Gross view as shown by photographs and histological analysis performed with hematoxylin and eosin staining. The negative control group indicates the normal
healthy group (n¼10). The AD control group indicates the group treated with phosphate-buffered saline alone as a vehicle control after induction of AD
(n¼10). The TA-and-quercetin-treated group (n¼10) showed significantly milder AD symptoms compared with the AD control group. The gross view and
histological analysis of the TA-and-quercetin-treated group are similar to those of the negative control group. Arrows indicate the AD site. Bar¼20 mm. (e) At the
treatment end points, the AD score of the TA-and-quercetin treatment group was lower than that of the nontreatment group (AD control). Data are reported as
mean±SD. *Po0.05, () control group versus AD control group; yPo0.05, AD control group versus TA-and-quercetin-treated group. (f) Angiogenesis levels
were detected by staining CD31 (red). The expression rate of CD31 in the TA-and-quercetin-treated group (n¼ 10) was significantly lower than that in the AD
control group (n¼ 10). The TA-and-quercetin-treated group (n¼10) showed patterns of CD31 expression that were fairly similar to those in the negative control
group (n¼ 10). Bar¼ 50 mm.
1460 Journal of Investigative Dermatology (2010), Volume 130
MK Jung et al.
Tannic Acid and Quercetin in Atopic Dermatitis
was significantly lower than that in
the AD control group (Figure 1f).
This is in agreement with the VEGF
expression pattern in vitro (Figure 1a–c).
These results indicate that TA and
quercetin lead to the inhibition of
neoangiogenesis, which may also
suppress chronic inflammation in AD-
like skin lesions.
AD is characterized as an inflamma-
tory Th2 polarity disorder (Howell
et al., 2007). Hence, we investigated
whether the cytokine thymic stromal
lymphopoietin (TSLP) correlates with the
therapeutic effect of TA and quercetin
in AD. TSLP induces Th2 cytokines,
including thymus and activation-
regulated chemokine (TARC), and is
involved in allergic responses, IgE
production, and eosinophilia (Liu,
2007). We measured the secretion of
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TSLP in TNF-a-stimulated human kerati-
nocytes using ELISA (R&D Systems,
Minneapolis, MN), and found that treat-
ment with TA and quercetin suppressed
TNF-a-induced TSLP expression (Figure 2a).
To further confirm that the combina-
tion of TA and quercetin regulates Th2
polarity, the TARC expression level was
also measured by ELISA (R&D Systems).
TARC has a role as a transporter of Th2
cells and is an important mediator
of AD (Sandoval-Lopez and Teran,
2001). However, the effects of TA
and quercetin on TARC production in
AD-like skin lesions are not yet known.
Our experiments indicate that treatment
with TA and quercetin results in a
marked decrease in TNF-a-induced
TARC levels in vitro and in vivo
(Figure 2b and c).
It is well known that an elevated
level of systemic serum IgE accompa-
nies AD-like skin lesions, and that its
production is affected by TSLP and
correlates with severity of AD (Liu,
2007; Morita et al., 1999). Because of
this, measurement of IgE is commonly
used to study AD severity. In our mouse
study, serum IgE was measured using
ELISA (Shibayagi, Shibukawa, Japan),
and we found that it was downregu-
lated in the group receiving TA and
quercetin treatment as compared with
the AD control group, which is in
agreement with the observation that
serum IgE level corresponded with AD
severity in mice with induced AD
(Figure 2c). On the basis of our results,
we hypothesize that TA and quercetin
may decrease Th2 polarization in AD.
Ultimately, this contributes to a better
balance between the Th1 and Th2
pathways, and regulation of this process
has a therapeutic effect on AD.
To our knowledge, this is the first
report demonstrating that TA and quer-
cetin have a therapeutic effect on AD
through suppression of angiogenesis
and Th2-related cytokine expression,
including TSLP and TARC, in an AD-
like Nc/Nga mouse model. We suggest
that TA and quercetin might be an
effective and improved therapeutic
strategy that should be investigated
further for treatment of AD. Future
studies are needed to investigate
whether the combination will have a
therapeutic effect on AD in humans.
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Figure 2. Inhibitory effect of tannic acid (TA) and quercetin on the production of thymic stromal lymphopoietin (TSLP), thymus and activation-regulated
chemokine (TARC), and IgE. (a) HaCaT cells and human primary keratinocytes were pretreated with or without tumor necrosis factor (TNF)-a (50 ngml1)
for 1 hour, followed by treatment with 25mM of TA and 5mM of quercetin, separately or in combination for 24 hours. The supernatant levels of TSLP and (b) TARC
were determined using ELISA kits. Results are from one representative experiment of three separate experiments. Data are reported as mean±SD. *Po0.05,
() control group versus TNF-a-treated group. yPo0.05, TNF-a-treated group versus TA-and-quercetin-treated group. (c) Treatment with or without TA (25mM)
and quercetin (2.5mM) applied three times a week to Nc/Nga mice with induced AD was observed for 3 weeks. The serum levels of TARC and IgE were
determined using specific ELISA kits. The TA-and-quercetin-treated group (n¼ 10) had lower serum TARC and IgE levels compared with the AD control
group (n¼ 10). Results are from one representative experiment of three separate experiments. Data are reported as mean±SD. *Po0.05, () control group
versus AD control group; yPo0.05, AD control group versus TA-and-quercetin-treated group.
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Relationship between Germline MC1R Variants and
BRAF-Mutant Melanoma in a North Carolina
Population-Based Study
Journal of Investigative Dermatology (2010) 130, 1463–1465; doi:10.1038/jid.2009.410; published online 31 December 2009
TO THE EDITOR
A few previous studies have examined
the relationship between germline mela-
nocortin-1 receptor (MC1R) status and
somatic BRAF mutations in melanoma.
Two publications reported strong associa-
tions in three independent populations
(two from Italy and one from San
Francisco) (Landi et al., 2006; Fargnoli
et al., 2008), whereas a more recent
publication found no association in an
Australian population-based study (Hacker
et al., 2010). We report our finding of no
significant association between MC1R
status and BRAF-mutant melanomas in a
population-based study of malignant mel-
anoma in North Carolina.
Participants in this study were
219 cases with first primary invasive
cutaneous melanoma from North Car-
olina, one site in the population-based
Genes, Environment, and Melanoma
(GEM) study (Begg et al., 2006). The
study protocol was approved by the
institutional review board of the Uni-
versity of North Carolina at Chapel Hill.
The Declaration of Helsinki protocols
were followed, and patients gave their
written, informed consent. The partici-
pants were interviewed regarding their
risk factors (Thomas et al., 2007). The
subjects were asked to have the nevi on
their backs counted by a family mem-
ber or friend, using a glossy colored
guide to aid in differentiating between
nevi and other skin lesions.
One dermatopathologist (KB) re-
viewed the tumors for standard histolo-
gical features. The tumors were scored
Abbreviations: adj., adjusted; CI, confidence interval; CSD, chronic sun damage; MC1R, melanocortin-1
receptor; OR, odds ratio; wt, wild type
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